1. Academic Validation
  2. Discovery of XL888: a novel tropane-derived small molecule inhibitor of HSP90

Discovery of XL888: a novel tropane-derived small molecule inhibitor of HSP90

  • Bioorg Med Chem Lett. 2012 Sep 1;22(17):5396-404. doi: 10.1016/j.bmcl.2012.07.052.
Joerg Bussenius 1 Charles M Blazey Naing Aay Neel K Anand Arlyn Arcalas TaeGon Baik Owen J Bowles Chris A Buhr Simona Costanzo Jeffrey K Curtis Steven C DeFina Larisa Dubenko Timothy S Heuer Ping Huang Christopher Jaeger Anagha Joshi Abigail R Kennedy Angie I Kim Katherine Lara Jae Lee Jonathan Li Julie C Lougheed Sunghoon Ma Shiva Malek Jean-Claire L Manalo Jean-Francois Martini Garth McGrath Monique Nicoll John M Nuss Michael Pack Csaba J Peto Tsze H Tsang Longcheng Wang Scott W Womble Michael Yakes Wentao Zhang Kenneth D Rice
Affiliations

Affiliation

  • 1 Exelixis, Inc., 220 East Grand Ave., South San Francisco, CA 94080, USA.
Abstract

With structural guidance, tropane-derived HTS hits were modified to optimize for HSP90 inhibition and a desirable in vivo profile. Through an iterative SAR development process 12i (XL888) was discovered and shown to reduce HSP90 client protein content in PD studies. Furthermore, efficacy experiments performed in a NCI-N87 mouse xenograft model demonstrated tumor regression in some dosing regimens.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-13313
    99.62%, HSP 抑制剂
    HSP